2 active not recruiting, 2 recruiting, 2 terminated. 3 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
Follow Mature B-cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Mature B-cell Non-Hodgkin Lymphoma trials Research Report on Mature B-cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone - Mature B-cell Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 87 | 2025-07-01 | 2026-06-04 |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Obinutuzumab, Glofitamab, Rituximab - Mature B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 65 | 2022-11-16 | 2026-10-06 |
| A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Antengene (Hangzhou) Biologics Co., Ltd. | 33 | 2022-01-30 | 2025-08-29 |
| A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Antengene Biologics Limited | 31 | 2021-12-15 | 2025-06-09 |
| Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Rituximab window, Additional doses of Rituximab, Cyclophosphamide - Mature B-cell Non-Hodgkin Lymphoma | Phase 3 | Active not recruiting | University Hospital Muenster | 650 | 2017-08-03 | 2026-04-30 |
| BNHL-2015 for Children or Adolescents in China Prednisone,Vincristine, Cyclophosphamide, Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone - Mature B-cell Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Active not recruiting | Children's Cancer Group, China | 200 | 2015-01-01 | 2026-03-19 |
Lymphoma (2) · Neoplasm Metastasis (2) · Recurrence (1)
Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms by Histologic Type (2) · Neoplastic Processes (2) · Disease Attributes (1)
Etoposide (4) · Cyclophosphamide (3) · Cytarabine (3) · Methotrexate (3) · Vincristine (3) · Ifosfamide (2) · Prednisone (2) · Rituximab (2) · Carboplatin (1) · Dexamethasone (1) · Doxorubicin (1) · Prednisolone (1) · Vindesine (1) · glofitamab (1) · obinutuzumab (1)
Children's Cancer Group, China (2) · Antengene (Hangzhou) Biologics Co., Ltd. (1) · Antengene Biologics Limited (1) · Hoffmann-La Roche (1) · University Hospital Muenster (1)
China (4) · Australia (2) · Czechia (2) · Denmark (2) · Germany (2) · United States (2) · Austria (1) · Brazil (1) · Finland (1) · France (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1) · South Korea (1)
Birgit Burkhardt, Prof. Dr. Dr. (1) · Hao Cui, MD (1) · Yi-Jin Gao, MD (1) · Yi-jin Gao (1)
PMID 10552938, PMID 15486066, PMID 20516455, PMID 22940833, PMID 35829780